Cited by 562Retinal Diseases and TreatmentsRetinal and Macular SurgeryOcular Diseases and Behçet’s Syndrome

The DOI matches its Crossref record; 9 of the 10 references it cites were found in a registry or an index.

Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results

Open access

Elman, Michael J., Ayala, Allison, Bressler, Neil M., Browning, David, Flaxel, Christina J., Glassman, Adam R., Jampol, Lee M., Stone, Thomas W.·2015·Ophthalmology

DOI 10.1016/j.ophtha.2014.08.047PMC PMC4520307

Open this paper in CoChat — free account

Abstract

Objective To report 5-year results from a previously reported trial evaluating intravitreal 0.5 mg ranibizumab with prompt versus deferred (for ≥24 weeks) focal/grid laser treatment for diabetic macular edema (DME).Design Multicenter, randomized clinical trial.Participants Among participants from the trial with 3 years of follow-up who subsequently consented to a 2-year extension and survived through 5 years, 124 (97%) and 111 (92%) completed the 5-year visit in the prompt and deferred groups, respectively.Methods Random assignment to ranibizumab every 4 weeks until no longer improving (with resumption if worsening) and prompt or deferred (≥24 weeks) focal/grid laser treatment.Main outcome measures Best-corrected visual acuity at the 5-year visit.Results The mean change in visual acuity letter score from baseline to the 5-year visit was +7.2 letters in the prompt laser group compared with +9.8 letters in the deferred laser group (mean difference, -2.6 letters; 95% confidence interval, -5.5 to +0.4 letters; P = 0.09). At the 5-year visit in the prompt versus deferred laser groups, there was vision loss of ≥10 letters in 9% versus 8%, an improvement of ≥10 letters in 46% versus 58%, and an improvement of ≥15 letters in 27% versus 38% of participants, respectively. From baseline to 5 years, 56% of participants in the deferred group did not receive laser. The median number of injections was 13 versus 17 in the prompt and deferral groups, including 54% and 45% receiving no injections during year 4 and 62% and 52% receiving no injections during year 5, respectively.Conclusions Five-year results suggest focal/grid laser treatment at the initiation of intravitreal ranibizumab is no better than deferring laser treatment for ≥24 weeks in eyes with DME involving the central macula with vision impairment. Although more than half of eyes in which laser treatment is deferred may avoid laser for at least 5 years, such eyes may require more injections to achieve these results when following this protocol. Most eyes treated with ranibizumab and either prompt or deferred laser maintain vision gains obtained by the first year through 5 years with little additional treatment after 3 years.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ophtha.2014.08.047

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Elman, M. J., Aiello, L. P., Beck, R. W., Bressler, N. M., Bressler, S. B., Edwards, A. R., Ferris, F. L., Friedman, S. M., Glassman, A. R., Miller, K. M., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.031 · Cited by 1,431
Self-citation
The RESTORE Study
Mitchell, P., Bandello, F. M., Schmidt-Erfurth, U. M., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.031 · Cited by 1,344
Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Elman, M. J., Bressler, N. M., Qin, H., Beck, R. W., Ferris, F. L., Friedman, S. M., Glassman, A. R., Scott, I. U., Stockdale, C. R., & Sun, J. K. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.033 · Cited by 572
Self-citation
Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment
Elman, M. J., Qin, H., Aiello, L. P., Beck, R. W., Bressler, N. M., Ferris, F. L., Glassman, A. R., Maturi, R. K., & Melia, M. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.08.022 · Cited by 322
Self-citation
Mixed models for longitudinal data
Cecílio‐Fernandes, D., Tio, R. A., & Jaarsma, D. A. D. C. (2016) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 118
Reproducibility of Spectral-Domain Optical Coherence Tomography Retinal Thickness Measurements and Conversion to Equivalent Time-Domain Metrics in Diabetic Macular Edema
Bressler, S. B., Edwards, A. R., Chalam, K. V., Bressler, N. M., Glassman, A. R., Jaffe, G. J., Melia, M., Saggau, D. D., & Plous, O. Z. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.1698 · Cited by 105
Self-citation
Inference for the Marginal Model
(2009) · Springer series in statistics · doi:10.1007/978-1-4419-0300-6_6 · Cited by 6

Flagged first, then by citations

Show all 10 references

1 of the 10 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 560

Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes
Laugesen, C. S., Ostri, C., Brynskov, T., Lund‐Andersen, H., Larsen, M., Vorum, H., & Sørensen, T. L. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13160 · Cited by 28
Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema
Holden, S. E., Currie, C. J., & Owens, D. R. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1366645 · Cited by 28
Retinal Reflectivity Measurement for Cone Impairment Estimation and Visual Assessment After Diabetic Macular Edema Resolution (RECOVER-DME)
Guyon, B., Elphege, E., Flores, M., Gauthier, A.-S., Delbosc, B. Y., & Saleh, M. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22380 · Cited by 28
Imaging Modalities Employed in Diabetic Retinopathy Screening: A Review and Meta-Analysis
Kanclerz, P., Tuuminen, R., & Khoramnia, R. (2021) · Diagnostics · doi:10.3390/diagnostics11101802 · Cited by 31
Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema
Hanhart, J., & Chowers, I. (2015) · Case Reports in Ophthalmology · doi:10.1159/000375230 · Cited by 27
Ranibizumab in diabetic macular edema
Krispel, C. M. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i6.310 · Cited by 27
Diabetic macular edema: Current management 2013
Arévalo, J. F. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i6.231 · Cited by 27
Evidence-Based Treatment of Diabetic Macular Edema
Barham, R., Rami, H. E., Sun, J. K., & Silva, P. S. (2017) · Seminars in Ophthalmology · doi:10.1080/08820538.2016.1228388 · Cited by 27
Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab
Ashraf, M., Souka, A., & Elkayal, H. E. (2017) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20170301-06 · Cited by 29
Vitrectomy in the management of diabetic macular edema in treatment-naïve patients
Michalewska, Z., Stewart, M. W., Landers, M. B., Bednarski, M., Adelman, R. A., & Nawrocki, J. (2017) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2017.10.011 · Cited by 28
Ranibizumab 0.3 mg for Persistent Diabetic Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial
Fechter, C., Frazier, H., Marcus, W. B., Farooq, A., Singh, H., & Marcus, D. M. (2016) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20161031-07 · Cited by 26
One-Year Results of Treatment of Diabetic Macular Edema with Aflibercept Using the Treat-and-Extend Dosing Regimen: the VIBIM Study
Pak, K. Y., Shin, J. P., Kim, H. W., Sagong, M., Kim, Y. C., Lee, S. J., Chung, I. Y., Park, S. W., & Lee, J. E. (2020) · Ophthalmologica · doi:10.1159/000504753 · Cited by 26
Multiple factors in the prediction of risk of recurrent vitreous haemorrhage after sutureless vitrectomy for non-clearing vitreous haemorrhage in patients with diabetic retinopathy
Ding, Y., Yao, B., Hang, H., & Ye, H. (2020) · BMC Ophthalmology · doi:10.1186/s12886-020-01532-8 · Cited by 26
Direct and indirect therapeutic effect of traditional Chinese medicine as an add-on for non-proliferative diabetic retinopathy: a systematic review and meta-analysis
An, X., Jin, D., Duan, L., Zhao, S., Zhou, R., Lian, F., & Tong, X. (2020) · Chinese Medicine · doi:10.1186/s13020-020-00380-4 · Cited by 26
Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines
Das, T., Aurora, A., Chhablani, J. K., Anantharaman, G., Kumar, A., Raman, R., Nagpal, M. P., Narayanan, R., Natarajan, S., Ramasamay, K., et al. (2016) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.178142 · Cited by 26
Association of Plasma Semaphorin 3A With Phenotypes of Diabetic Retinopathy and Nephropathy
Kwon, S. H., Shin, J. P., Kim, I. T., & Park, D. H. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19468 · Cited by 26
Diabetic macular oedema treated with intravitreal anti‐vascular endothelial growth factor – 2–4 years follow‐up of visual acuity and retinal thickness in 566 patients following Danish national guidelines
Hodzic‐Hadzibegovic, D., Sander, B., Monberg, T. J., Larsen, M., & Lund‐Andersen, H. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13638 · Cited by 26
Vascular Regeneration for Ischemic Retinopathies: Hope from Cell Therapies
Bertelli, P. M., Pedrini, E., Guduric‐Fuchs, J., Peixoto, E., Pathak, V., Stitt, A. W., & Medina, R. J. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1681004 · Cited by 26
A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser only in centre-involving diabetic macular oedema (OZLASE study)
Heng, L. Z., Sivaprasad, S., Crosby‐Nwaobi, R., Saihan, Z., Karampelas, M. D., Bunce, C., Pető, T., & Hykin, P. G. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-307136 · Cited by 25
Extended duration strategies for the pharmacologic treatment of diabetic retinopathy: current status and future prospects
Stewart, M. W., Flynn, H. W., Schwartz, S. G., & Scott, I. U. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1198771 · Cited by 25
Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies
Staurenghi, G., Feltgen, N., Arnold, J., Katz, T. A., Metzig, C., Lu, C., & Holz, F. G. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-310664 · Cited by 25
Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?
Das, A., McGuire, P. G., & Monickaraj, F. (2016) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.178154 · Cited by 25
Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema
Shimizu, N., Oshitari, T., Tatsumi, T., Takatsuna, Y., Arai, M., Sato, E., Baba, T., & Yamamoto, S. (2017) · BioMed Research International · doi:10.1155/2017/1747108 · Cited by 25
From randomised controlled trials to real-world data: Clinical evidence to guide management of diabetic macular oedema
Gabrielle, P., Mehta, H., Barthelmes, D., Daïen, V., Nguyen, V., Gillies, M. C., & Creuzot-Garcher, C. P. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2023.101219 · Cited by 25
Emerging roles for antiangiogenesis factors in management of ocular disease
Saeed, M. U., Gkaragkani, & Ali (2013) · Clinical ophthalmology · doi:10.2147/opth.s31016 · Cited by 24
Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema
Bressler, N. M., Varma, R., Mitchell, P., Suñer, I. J., Dolan, C., Ward, J., Ferreira, A., Ehrlich, J. S., & Turpcu, A. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.4636 · Cited by 24
Self-citation
Identification of time point to best define ‘sub-optimal response’ following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data
Chatziralli, I., Santarelli, M., Patrao, N. V., Nicholson, L., Zola, M., Rajendram, R., Hykin, P. G., & Sivaprasad, S. (2017) · Eye · doi:10.1038/eye.2017.111 · Cited by 24
Evidence-Based Guidelines for Management of Diabetic Macular Edema
Bakri, S. J., Wolfe, J. D., Regillo, C. D., Flynn, H. W., & Wykoff, C. C. (2019) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126419834711 · Cited by 24
Real world evidence of use of anti-VEGF therapy in Denmark
Vorum, H., Olesen, T. K., Zinck, J., & Hedegaard, M. S. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1221803 · Cited by 24
Vitrectomy for center-involved diabetic macular edema
Browning, D. J., Lee, C., Stewart, M., & Landers, M. B. (2016) · Clinical ophthalmology · doi:10.2147/opth.s104906 · Cited by 24
Self-citation
Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study)
Menchini, U., Bandello, F. M., Angelis, V. D., Ricci, F., Bonavia, L., Viola, F., Muscianisi, E., & Nicolò, M. (2015) · Journal of Ophthalmology · doi:10.1155/2015/324841 · Cited by 23
Hyperreflective Walls in Foveal Cystoid Spaces as a Biomarker of Diabetic Macular Edema Refractory to Anti-VEGF Treatment
Terada, N., Murakami, T., Uji, A., Dodo, Y., Mori, Y., & Tsujikawa, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-64332-6 · Cited by 23
Current perspectives on ranibizumab
Bakri, S. J., & Dedania, V. S. (2015) · Clinical ophthalmology · doi:10.2147/opth.s80049 · Cited by 23
Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents in lower-middle-income countries
Ghoraba, H. H., Leila, M., Elgouhary, S. M., Elgemai, E. E. M., Abdelfattah, H. M., Ghoraba, H. H., & Heikal, M. A. (2018) · Clinical ophthalmology · doi:10.2147/opth.s185274 · Cited by 24
Real-World Outcomes with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study
Massin, P., Creuzot-Garcher, C. P., Kodjikian, L., Girmens, J., Delcourt, C., Fajnkuchen, F., Glacet-Bernard, A., Guillausseau, P.-J., Ponthieux, A., Blin, P., et al. (2019) · Ophthalmic Research · doi:10.1159/000497406 · Cited by 23
Preventive factors, diagnosis, and management of injection-related endophthalmitis: a literature review
Singh, R., Davoudi, S., & Ness, S. D. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05607-8 · Cited by 28
South Asian diabetic macular oedema treated with ranibizumab (ADMOR)—real-life experience
Ghanchi, F. D., & Hazel, C. (2015) · Eye · doi:10.1038/eye.2015.209 · Cited by 22
Updates on the clinical trials in diabetic macular edema
Nguyen, Q. D., Demirel, S., Argo, C., Agarwal, A. K., Parriott, J. E., Sepah, Y. J., & Do, D. (2015) · Middle East African Journal of Ophthalmology · doi:10.4103/0974-9233.172293 · Cited by 22
Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option
Ashraf, M., Souka, A., Adelman, R. A., & Forster, S. H. (2016) · Eye · doi:10.1038/eye.2016.174 · Cited by 22
Outcomes after a 1-Year Treatment with Ranibizumab for Diabetic Macular Edema in a Clinical Setting
Hrarat, L., Fajnkuchen, F., Boubaya, M., Lévy, V., Sarda, V., Grenet, T., Nghiem‐Buffet, S., Chaine, G., & Giocanti‐Auregan, A. (2016) · Ophthalmologica · doi:10.1159/000453006 · Cited by 22
Outcomes of Diabetic Macular Edema Patients by Baseline Hemoglobin A1c
Singh, R. P., Wykoff, C. C., Brown, D. M., Larsen, M., Terasaki, H., Silva, F. Q. D. P. A., Saroj, N., Gibson, A., Vitti, R., Kayshap, S., et al. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.02.003 · Cited by 22
Real-world management of treatment-naïve diabetic macular oedema: 2-year visual outcome focusing on the starting year of intervention from STREAT-DMO study
Shimura, M., Kitano, S., Muramatsu, D., Fukushima, H., Takamura, Y., Matsumoto, M., Kokado, M., Kogo, J., Sasaki, M., Morizane, Y., et al. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-315726 · Cited by 22
Optimal treatment of diabetic retinopathy
Hammes, H. (2013) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018813477886 · Cited by 24
Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results
Payne, J. F., Wykoff, C. C., Clark, W. L., Bruce, B. B., Boyer, D. S., & Brown, D. M. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316176 · Cited by 21
Triamcinolone acetonide modulates TGF‑β2‑induced angiogenic and tissue‑remodeling effects in cultured human retinal pigment epithelial cells
Hsiao, C., Chang, Y., Hsiao, Y., Chen, P.-H., Hsieh, M.-C., Wu, W., & Kao, Y. H. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12442 · Cited by 21
Treat-and-Extend vs. Pro Re Nata Regimen of Ranibizumab for Diabetic Macular Edema—A Two-Year Matched Comparative Study
Lai, T., Chen, T., Yang, C., Yang, C., Ho, T., & Hsieh, Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.781421 · Cited by 21
The Role of Laser Photocoagulation in Treating Diabetic Macular Edema in the Era of Intravitreal Drug Administration: A Descriptive Review
Nozaki, M., Ando, R., Kimura, T., Kato, F., & Yasukawa, T. (2023) · Medicina · doi:10.3390/medicina59071319 · Cited by 21
Exploring the role of retinal fluid as a biomarker for the management of diabetic macular oedema
Khoramnia, R., Nguyen, Q. D., Kertes, P. J., Sararols, L., Vujosevic, S., Anderesi, M., Igwe, F., & Eter, N. (2023) · Eye · doi:10.1038/s41433-023-02637-2 · Cited by 21
Diabetic Macular Edema: Options for Adjunct Therapy
Calvo, P., Abadía, B., Ferreras, A., Ruiz‐Moreno, Ó., Verdes, G., & Pablo, L. E. (2015) · Drugs · doi:10.1007/s40265-015-0447-1 · Cited by 21
Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant
Cebeci, Z., & Kır, N. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s73540 · Cited by 21
Two year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocol
Sugimoto, M., Ichio, A., Nunome, T., & Kondo, M. (2017) · Medicine · doi:10.1097/md.0000000000006406 · Cited by 21
Effect of ripasudil on diabetic macular edema
Minami, Y., Song, Y., Ishibazawa, A., Omae, T., Ro-Mase, T., Ishiko, S., & Yoshida, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-40194-5 · Cited by 21
Current concepts of pharmacotherapy of diabetic macular edema
Haritoglou, C., Maier, M. M., Neubauer, A. S., & Augustin, A. J. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1713093 · Cited by 21
Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding
Farah, J. D. L., Sano, R. Y., Longo‐Maugéri, I. M., Teixeira, D., Ishimura, M. E., Gomes, G. M. C., Mímica, L. M. J., da Silva, C. B., Meyer, C. H., Dias, J. R. D. O., et al. (2018) · International Journal of Retina and Vitreous · doi:10.1186/s40942-018-0143-x · Cited by 20
Long-term efficacy and duration of action of dexamethasone implant, in vitrectomised and non-vitrectomised eyes with persistent diabetic macular oedema
Bastakis, G. G., Dimopoulos, D., Stavrakakis, A., & Pappas, G. (2018) · Eye · doi:10.1038/s41433-018-0219-8 · Cited by 20
Diabetes mellitus type 1 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Nikonova, T. V., Sukhareva, O. Y., Пекарева, Е. В., Ibragimova, L. I., Mikhina, M. S., Galstyan, G. R., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12505 · Cited by 19
Treatment of Diabetic Macular Edema with Aflibercept and Micropulse Laser (DAM Study)
Koushan, K., Eshtiaghi, A., Fung, P., Berger, A. R., & Chow, D. R. (2022) · Clinical ophthalmology · doi:10.2147/opth.s360869 · Cited by 19
Predictor of Early Remission of Diabetic Macular Edema under As-Needed Intravitreal Ranibizumab
Yoshitake, T., Murakami, T., Suzuma, K., Fujimoto, M., Dodo, Y., & Tsujikawa, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-44078-6 · Cited by 20
Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients
Yaghi, N. E. A., Abed, A. M., Khlaifat, D. F., Nawaiseh, M. B., Emoush, L. O., AlHajjaj, H. Z., Abojaradeh, A. M., Hattar, M. N., Abusaleem, S. K., Sabbagh, H. M., et al. (2020) · Clinical ophthalmology · doi:10.2147/opth.s248661 · Cited by 19
Early and Long-term Responses to Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data
Ophir, A. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.11.025 · Cited by 19
International consensuses and controversies on causes, diagnosis and management of diabetic macular edema (DME)
Ng, D. S., Ruamviboonsuk, P., Apte, R. S., Bajimaya, S., Chan, C. K. M., Chang, A., Cheung, C. Y.-L., Chen, S. J., Chaudhary, V., Chaikitmongkol, V., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101406 · Cited by 18
Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data
Holekamp, N. M., Duff, S., Rajput, Y., & Garmo, V. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1666855 · Cited by 19
The Area and Number of Intraretinal Cystoid Spaces Predict the Visual Outcome after Ranibizumab Monotherapy in Diabetic Macular Edema
Nagai, N., Suzuki, M., Uchida, A., Kurihara, T., Ban, N., Minami, S., Shinoda, H., Tsubota, K., & Ozawa, Y. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051391 · Cited by 18
Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial
Garweg, J. G., Štefaničková, J., Hoyng, C. B., Niesen, T., Schmelter, T., Leal, S., Sivaprasad, S., the VIOLET Investigators, Schmidt-Erfurth, U. M., Wedrich, A., et al. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02119-z · Cited by 18
Relation between macular morphology and treatment frequency during twelve months with ranibizumab for diabetic macular edema
Mori, Y., Murakami, T., Suzuma, K., Ishihara, K., Yoshitake, S., Fujimoto, M., Dodo, Y., Yoshitake, T., Miwa, Y., & Tsujikawa, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175809 · Cited by 18
Safety and Efficacy of Ziv-Aflibercept in the Treatment of Refractory Diabetic Macular Edema
Ashraf, M., Elkayal, H. E., & Souka, A. (2017) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20170428-06 · Cited by 18
Real-life experience of ranibizumab for diabetic macular edema in Taiwan
Tsai, M., Hsieh, Y., & Peng, Y. (2018) · International Ophthalmology · doi:10.1007/s10792-018-0970-7 · Cited by 18
Optical Coherence Tomography Biomarkers in Bilateral Diabetic Macular Edema Patients with Asymmetric anti-VEGF Response
Koç, F., Güven, Y. Z., Eğrilmez, E. D., & Aydın, E. (2021) · Seminars in Ophthalmology · doi:10.1080/08820538.2021.1907423 · Cited by 17
Hypochlorous acid antiseptic washout improves patient comfort after intravitreal injection: A patient reported outcomes study
Finger, P. T., Fam, A., Tomar, A., Garg, G., & Chin, K. J. (2020) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2001_20 · Cited by 17
The Evolving Treatment Options for Diabetic Macular Edema
Jain, A., Varshney, N., & Smith, C. S. (2013) · International Journal of Inflammation · doi:10.1155/2013/689276 · Cited by 16
Prevalence of and risk factors for diabetic macular edema in a northeastern Chinese population
Zhong, L., Wen, L., Beijing Ophthalmology & Visual Science Key Lab, B. 1., Wang, Y., Beijing Ophthalmology & Visual Science Key Lab, B. 1., Li, D., Beijing Ophthalmology & Visual Science Key Lab, B. 1., Ding, X., Beijing Ophthalmology & Visual Science Key Lab, B. 1., Dou, Y., et al. (2022) · International Journal of Ophthalmology · doi:10.18240/ijo.2022.02.19 · Cited by 16
Comparative Effectiveness Trial for Diabetic Macular Edema
Jampol, L. M., Glassman, A. R., & Bressler, N. M. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.1880 · Cited by 16
Self-citation
Diabetic Macular Edema: Emerging Strategies and Treatment Algorithms
Moisseiev, E., & Loewenstein, A. (2017) · Developments in ophthalmology · doi:10.1159/000459706 · Cited by 16
Outcomes of Intravitreal Dexamethasone Implant in the Treatment of Recalcitrant Diabetic Macular Edema
Akıncıoğlu, D., Küçükevcilioğlu, M., Durukan, A. H., Aykaş, S., Ayyıldız, Ö., & Erdurman, F. C. (2017) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.28863 · Cited by 16
Therapeutic effect of simultaneous intravitreal dexamethasone and aflibercept on diabetic macular edema
Lin, T., Chung, Y.-C., Hsu, T.-K., Huang, H.-W., Huang, Y.-M., Chou, Y. C., Chao, C.-Y., & Tseng, P.-C. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01824-5 · Cited by 16
Advances in the management of diabetic macular oedema based on evidence from the Diabetic Retinopathy Clinical Research Network
Lim, L. T., Chia, S. N., Ah-kee, E. Y., Chew, N., & Gupta, M. (2015) · Singapore Medical Journal · doi:10.11622/smedj.2015071 · Cited by 16
Changing paradigms of anti-VEGF in the Indian scenario
Shanmugam, P. (2014) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.126189 · Cited by 16
Management of diabetic macular edema: experts’ consensus in Taiwan
Chen, J.-T., Chen, L.-J., Chen, S.-N., Cheng, C.-K., Cheng, C., Sheu, S., Sheu, S., Wu, W., Yang, C., Yang, C., et al. (2020) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-020-00741-4 · Cited by 16
Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema
Tatsumi, T., Takatsuna, Y., Oshitari, T., Kaiho, T., Kawasaki, Y., Shiko, Y., Sugawara, T., Baba, T., & Yamamoto, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-14444-y · Cited by 15
Deep learning to infer visual acuity from optical coherence tomography in diabetic macular edema
Lin, T., Chen, H.-R., Huang, H., Hsiao, Y.-I., Kao, Z.-K., Chang, K.-J., Lin, T., Yang, C., Kao, C., Chen, P.-Y., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1008950 · Cited by 15
Diabetic macular oedema quantified with spectral‐domain optical coherence tomography – evaluation of boundary line artefacts and the effect on retinal thickness
Hodzic‐Hadzibegovic, D., Sander, B., & Lund‐Andersen, H. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12494 · Cited by 15
Implantes intravítreos de dexametasona en pacientes con edema macular diabético refractario a ranibizumab en monoterapia o en combinación de tratamientos
Gutiérrez-Benítez, L., Millan, E. G., Arias, L., Garcia, P., Cobos, E., & Caminal-Caramés, M. (2015) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2015.04.003 · Cited by 15
Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema
Currie, C. J., Holden, S. E., & Owens, D. R. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1366662 · Cited by 15
Daten zur Behandlungsrealität des diabetischen Makulaödems mit Ranibizumab
Wilke, R. G. H., Finger, R. P., & Sachs, H. G. (2017) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/s-0043-115901 · Cited by 15
Impact of Intravitreal Ranibizumab Therapy on Vision Outcomes in Diabetic Macular Edema Patients: A Meta-Analysis
Falcão, M. S. (2019) · Ophthalmologica · doi:10.1159/000505070 · Cited by 15
Anatomical and functional responses in eyes with diabetic macular edema treated with “1 + PRN” ranibizumab: one-year outcomes in population of mainland China
Lai, K., Huang, C., Li, L., Gong, Y., Xu, F., Zhong, X., Lü, L., & Jin, C. (2020) · BMC Ophthalmology · doi:10.1186/s12886-020-01510-0 · Cited by 15
The Interval between Treatments of Bevacizumab and Dexamethasone Implants for Diabetic Macular Edema Increased over Time in the BEVORDEX Trial
Mehta, H., Fraser‐Bell, S., Nguyen, V., Lim, L. L., & Gillies, M. C. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.06.010 · Cited by 15
Diabetic retinopathy in focus: Update on treatment advances, pharmaceutical approaches, and new technologies
Ciorba, A. L., Saber, S., Abdelhamid, A. M., Keshk, N., Elnaghy, F., Elmorsy, E. A., Abu‐Khudir, R., Hamad, R. S., Abdel‐Reheim, M. A., Farrag, A. A. M., et al. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107307 · Cited by 19
TEMPORARY REMOVAL: Four-Year Outcomes of Faricimab in Diabetic Macular Edema
Sheth, V. S., Schlottmann, P. G., Lai, T. Y. Y., Abreu, F. M., Chang, A., Eter, N., Gibson, K., Hu, A. Y. H., Korobelnik, J., Kotak, A., et al. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.01.001 · Cited by 14
Retracted
3-year-data of combined navigated laser photocoagulation (Navilas) and intravitreal ranibizumab compared to ranibizumab monotherapy in DME patients
Herold, T., Langer, J., Vounotrypidis, E., Kernt, M., Liegl, R., & Priglinger, S. G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202483 · Cited by 14
Efficacy and Cost-Effectiveness of Anti-VEGF for Treating Diabetic Retinopathy in the Indian Population
Pramanik, S., Mondal, L. K., Paine, S. K., Jain, S., Chowdhury, S., Ganguly, U., Ghosh, S., Bose, C., Bhattacharjee, K., & Bhaduri, G. (2021) · Clinical ophthalmology · doi:10.2147/opth.s317771 · Cited by 15
Effectiveness of Suprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema Using a Modified Microneedle
Nawar, A. E. (2022) · Clinical ophthalmology · doi:10.2147/opth.s391319 · Cited by 14
Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study
Séjournet, L., Kodjikian, L., Elbany, S., Allignet, B., Agard, É., Chaperon, M., Billant, J., Denis, P., Mathis, T., Burillon, C., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020308 · Cited by 14
Intravitreal therapy of diabetic macular edema in Russian Federation: current state of the problem
Липатов, Д. В., & Lyshkanets, O. I. (2019) · Russian Annals of Ophthalmology · doi:10.17116/oftalma2019135041128 · Cited by 14
Endothelial Cells Derived From Patients With Diabetic Macular Edema Recapitulate Clinical Evaluations of Anti-VEGF Responsiveness Through the Neuronal Pentraxin 2 Pathway
González, M. V., Eleftheriadou, M., Kelaini, S., Naderi‐Meshkin, H., Flanagan, S., Stewart, S., Virgili, G., Grieve, D., Stitt, A. W., Lois, N., et al. (2020) · Diabetes · doi:10.2337/db19-1068 · Cited by 14
Netzhautkomplikationen bei Diabetes
Bertram, B., Lemmen, K. D., Agostini, H. T., Ziemssen, F., Hammes, H., & Landgraf, R. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0140-3 · Cited by 14
Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser Photocoagulation for Diabetic Macular Edema
Wykoff, C. C., Marcus, D. M., Midena, E., Korobelnik, J., Saroj, N., Gibson, A., Vitti, R., Berliner, A. J., Liu, Z. W., Zeitz, O., et al. (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.4912 · Cited by 14
Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes
Currie, C. J., Holden, S. E., Berni, E. R., & Owens, D. R. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1366659 · Cited by 14
Pars Plana Vitrectomy with Internal Limiting Membrane Peeling for Nontractional Diabetic Macular Edema
Ulrich, J. (2017) · The Open Ophthalmology Journal · doi:10.2174/1874364101711010005 · Cited by 13
Ursodeoxycholic Acid Attenuates the Retinal Vascular Abnormalities in Anti-PDGFR-β Antibody-Induced Pericyte Depletion Mouse Models
Shiraya, T., Araki, F., Ueta, T., Fukunaga, H., Totsuka, K., Arai, T., Uemura, A., Moriya, K., & Kato, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-58039-x · Cited by 16

Authors: Elman, M. J., Ayala, A., Bressler, N. M., Browning, D., Flaxel, C. J., Glassman, A. R., Jampol, L. M., & Stone, T. W.
Affiliations: Elman Retina Group (US)
Jaeb Center for Health Research (US)
Johns Hopkins University (US)
Charlotte Eye Ear Nose & Throat Associates (US)
Northwestern University (US)
Retina Associates of Kentucky (US)
Corresponding author: Ayala, Allison
ORCID: Elman, Michael J.
Ayala, Allison
Bressler, Neil M.
Browning, David
Flaxel, Christina J.
Glassman, Adam R.
Jampol, Lee M.
Venue: Ophthalmology
Publisher: Elsevier BV
Published: 2015-02
Volume: 122
Issue: 2
Pages: 375-381
ISSN: 0161-6420 (ISSN-L)
DOI: 10.1016/j.ophtha.2014.08.047
PMC: PMC4520307
OpenAlex: W1980342089
Cited by: 562
References: 10
Citations by year: 2026: 8 · 2025: 18 · 2024: 22 · 2023: 20 · 2022: 35 · 2021: 39 · 2020: 55 · 2019: 41 · 2018: 45 · 2017: 79 · 2016: 72 · 2015: 73
FWCI: 79.09
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Ophthalmology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Eye Institute (EY14231, EY-14229, EY18817, EY023207, U10EY018817, U10EY014229, U10EY023207, U10EY014231, UG1EY014231)
Topics: Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords: diabetic macular edema, ranibizumab, intravitreal injection, best-corrected visual acuity, long-term visual outcomes, anti-VEGF therapy, vision loss, treatment duration extension, retinal laser treatment, anti-angiogenic therapy, treatment burden reduction
MeSH terms: Ranibizumab, Aged, Combined Modality Therapy, Diabetic Retinopathy, Female, Humans, Macular Edema, Male, Middle Aged, Visual Acuity, Treatment Outcome, Laser Coagulation, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Intravitreal Injections, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks